GlassScriptPhysician profile
Martin Greenfield
NPI 1205831443
$2,932.66
in general payments reported to CMS, 2019-2025
24 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $100 · 2021: $635 · 2022: $1,055 · 2023: $196 · 2024: $33.58 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $573.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $327.90 | 2019-2022 | |
| Amgen INC. | $233.29 | 2019-2025 | Evenity |
| Abbvie INC. | $225.38 | 2019-2024 | |
| Lilly USA, LLC | $217.56 | 2019-2023 | Jardiance, Mounjaro |
| Medtronic, INC. | $192.54 | 2021-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.03 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $136.17 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $125.54 | 2022-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $117.17 | 2022-2023 | Gvoke Hypopen |
| Insulet Corporation | $106.76 | 2019-2022 | |
| Abbott Laboratories | $92.37 | 2021-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $92.07 | 2021-2022 | |
| Becton, Dickinson and Company | $76.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $53.33 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.22 | 2019-2020 | |
| Lifescan, INC. | $35.27 | 2019-2021 | |
| Embecta Corp. | $23.53 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Tandem Diabetes Care, INC. | $19.96 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $19.18 | 2022 | |
| Ibsa Pharma INC. | $17.10 | 2021 | |
| Pfizer INC. | $15.20 | 2022 | |
| Medtronic Minimed, INC. | $14.35 | 2020 | |
| Mannkind Corporation | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Greenfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.